Table. Descriptive Characteristics of 22 Oral Anticancer Drugs Analyzed for Drug Wastage.
| Characteristic | Drugs analyzed, No. (%) |
|---|---|
| Total No. of clinical trials analyzed | 35 |
| Drug target | |
| KIT plus PDGFRA | 3 (9) |
| EGFR | 4 (12) |
| FGFR | 3 (9) |
| PARP | 7 (21) |
| Other | 17 (50) |
| Indication | |
| Breast cancer | 4 (12) |
| NSCLC | 9 (26) |
| Ovarian cancer | 3 (9) |
| Prostate cancer | 3 (9) |
| Other | 15 (44) |
| Patients exposed to drug, median (IQR), No. | 204 (106-320) |
| Level of dose reduction | |
| None, not allowed | 2 (5.9) |
| 1 | 9 (28) |
| 2 | 19 (59) |
| 3 | 4 (12) |
| Drugs divisible at each dose level | 8 (24) |
| Duration of treatment, median (IQR), mo | 9 (6-19) |
| Dose modification | |
| Received dose reduction, median (IQR), % | 24 (11-32) |
| Permanently discontinued drug, median (IQR), % | 10 (7-16) |
| Cost | |
| Dose reduction, median (IQR), $ | 654 291 (231 486-1 403 392) |
| Permanent discontinuation, median (IQR), $ | 184 452 (121 840-281 407) |
| Wastage per patient, median (IQR), $ | 1751 (1096-5195) |
| Drug wastage in trial, median (IQR), % | 1.04 (0.55-1.89) |
Abbreviations: EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; KIT, V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; NSCLC, non–small cell lung cancer; PARP, poly (ADP-ribose) polymerase; PDGFRA, platelet-derived growth factor receptor alpha.